BioLineRx Reports Peer-Reviewed Publication of Phase 1/2 Trial Results for Novel Treatment for Non-Surgical Removal of Skin Lesions
June 01, 2015 at 07:04 AM EDT
BioLineRx Ltd. (NASDAQ: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing ...